|
|
|
| Market Analysis and Countermeasures for Targeted Protein Degradation Drugs |
LIU Shao-jin1,**( ),DOU Shu-zhen1,WANG Jun-shu1,WU Hai-ming2,ZOU Hui1 |
1 Institute of Science and Technology Strategy, Jiangxi Academy of Sciences, Nanchang 330096, China
2 Halocinch Medical Technology (Shenzhen) Co., Ltd, Shenzhen 518109, China |
|
|
|
Abstract Targeted protein degradation technology breaks the limitations of traditional therapies and is considered to be a revolutionary technology in the field of biomedicine due to its high activity, high selectivity and targeting of “undruggable”targets. It has developed into one of the most cutting-edge and effective disease treatment strategies. In the past two decades, various degradation technologies based on targeted protein degradation systems have been emerging. Among them, small molecule targeted protein degradation drugs, represented by molecular glues and proteolysis-targeting chimeras, have made rapid progress. A large number of clinical trials and evaluations have fully confirmed the universality and effectiveness of targeted protein degradation. The technology brings new potential treatment options for some “incurable” diseases, and has great development and utilization value and market potential. In order to further promote the innovation and development of China’s targeted protein degradation drug industry, quantitative and qualitative combination of analytical methods are used in this paper to deeply analyze the current situation and market trends of technology and product research and development of targeted protein degradation drugs industry domestically and overseas. Meanwhile, targeted countermeasures are put forward from the perspective of future breakthrough direction and institutional mechanism innovation.
|
|
Received: 12 October 2022
Published: 31 March 2023
|
|
|
|
Corresponding Authors:
**Shao-jin LIU
E-mail: liusj9112@126.com
|
|
|
| [1] |
Burslem G M, Crews C M. Small-molecule modulation of protein homeostasis. Chemical Reviews, 2017, 117(17): 11269-11301.
doi: 10.1021/acs.chemrev.7b00077
pmid: 28777566
|
|
|
| [2] |
Verdine G L, Walensky L D. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 2007, 13(24): 7264-7270.
doi: 10.1158/1078-0432.CCR-07-2184
|
|
|
| [3] |
Samarasinghe K T G, Crews C M. Targeted protein degradation: a promise for undruggable proteins. Cell Chemical Biology, 2021, 28(7): 934-951.
doi: 10.1016/j.chembiol.2021.04.011
pmid: 34004187
|
|
|
| [4] |
Cromm P M, Crews C M. Targeted protein degradation: from chemical biology to drug discovery. Cell Chemical Biology, 2017, 24(9): 1181-1190.
doi: S2451-9456(17)30187-3
pmid: 28648379
|
|
|
| [5] |
Naito M. Targeted protein degradation and drug discovery. The Journal of Biochemistry, 2022, 172(2): 61-69.
doi: 10.1093/jb/mvac041
|
|
|
| [6] |
张晓元, 张艳艳, 孙晓康, 等. 靶向蛋白质降解技术研究进展. 生物化学与生物物理进展, 2022, 49(1): 171-182.
|
|
|
| [6] |
Zhang X Y, Zhang Y Y, Sun X K, et al. Research progress of targeted protein degradation technology. Progress in Biochemistry and Biophysics, 2022, 49(1): 171-182.
|
|
|
| [7] |
Wang C, Zhang Y J, Zhang T T, et al. Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37(1): 1667-1693.
doi: 10.1080/14756366.2022.2076675
pmid: 35702041
|
|
|
| [8] |
Xi J Y, Zhang R Y, Chen K, et al. Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery. Bioorganic Chemistry, 2022, 125: 105848.
doi: 10.1016/j.bioorg.2022.105848
|
|
|
| [9] |
Zhao L, Zhao J, Zhong K H, et al. Targeted protein degradation: mechanisms, strategies and application. Signal Transduction and Targeted Therapy, 2022, 7: 113.
doi: 10.1038/s41392-022-00966-4
pmid: 35379777
|
|
|
| [10] |
Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell, 1994, 79(1): 13-21.
doi: 10.1016/0092-8674(94)90396-4
pmid: 7923371
|
|
|
| [11] |
Ballabio A, Bonifacino J S. Lysosomes as dynamic regulators of cell and organismal homeostasis. Nature Reviews Molecular Cell Biology, 2020, 21(2): 101-118.
doi: 10.1038/s41580-019-0185-4
pmid: 31768005
|
|
|
| [12] |
Eldridge A G, O’Brien T. Therapeutic strategies within the ubiquitin proteasome system. Cell Death & Differentiation, 2010, 17(1): 4-13.
|
|
|
| [13] |
Gustafson J L, Neklesa T K, Cox C S, et al. Small-molecule-mediated degradation of the androgen receptor through hydrophobic tagging. Angewandte Chemie (International Ed in English), 2015, 54(33): 9659-9662.
doi: 10.1002/anie.v54.33
|
|
|
| [14] |
Weagel E G, Foulks J M, Siddiqui A, et al. Molecular glues: enhanced protein-protein interactions and cell proteome editing. Medicinal Chemistry Research, 2022, 31(7): 1068-1087.
doi: 10.1007/s00044-022-02882-2
|
|
|
| [15] |
Sakamoto K M, Kim K B, Kumagai A, et al. Protacs:Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98(15): 8554-8559.
|
|
|
| [16] |
Metzger M B, Pruneda J N, Klevit R E, et al. RING-type E3 ligases: master manipulators of E 2 ubiquitin-conjugating enzymes and ubiquitination. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2014, 1843(1): 47-60.
doi: 10.1016/j.bbamcr.2013.05.026
|
|
|
| [17] |
Luh L M, Scheib U, Juenemann K, et al. Prey for the proteasome: targeted protein degradation-a medicinal chemist’s perspective. Angewandte Chemie (International Ed in English), 2020, 59(36): 15448-15466.
|
|
|
| [18] |
Banik S M, Pedram K, Wisnovsky S, et al. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature, 2020, 584(7820): 291-297.
doi: 10.1038/s41586-020-2545-9
|
|
|
| [19] |
Cotton A D, Nguyen D P, Gramespacher J A, et al. Development of antibody-based PROTACs for the degradation of the cell-surface immune checkpoint protein PD-L1. Journal of the American Chemical Society, 2021, 143(2): 593-598.
doi: 10.1021/jacs.0c10008
pmid: 33395526
|
|
|
| [20] |
Zhang H, Han Y, Yang Y F, et al. Covalently engineered nanobody chimeras for targeted membrane protein degradation. Journal of the American Chemical Society, 2021, 143(40): 16377-16382.
doi: 10.1021/jacs.1c08521
pmid: 34596400
|
|
|
| [21] |
Takahashi D, Moriyama J, Nakamura T, et al. AUTACs: cargo-specific degraders using selective autophagy. Molecular Cell, 2019, 76(5): 797-810.e10.
doi: S1097-2765(19)30694-X
pmid: 31606272
|
|
|
| [22] |
Fu Y H, Chen N X, Wang Z Y, et al. Degradation of lipid droplets by chimeric autophagy-tethering compounds. Cell Research, 2021, 31(9): 965-979.
doi: 10.1038/s41422-021-00532-7
pmid: 34239073
|
|
|
| [23] |
Miao Y Y, Gao Q Q, Mao M H, et al. Bispecific aptamer chimeras enable targeted protein degradation on cell membranes. Angewandte Chemie (International Ed in English), 2021, 60(20): 11267-11271.
doi: 10.1002/anie.v60.20
|
|
|
| [24] |
Ji C H, Kim H Y, Lee M J, et al. The AUTOTAC chemical biology platform for targeted protein degradation via the autophagy-lysosome system. Nature Communications, 2022, 13: 904.
doi: 10.1038/s41467-022-28520-4
pmid: 35173167
|
|
|
| [25] |
Lin J Y, Jin J M, Shen Y W, et al. Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins. Theranostics, 2021, 11(17): 8337-8349.
doi: 10.7150/thno.62686
pmid: 34373745
|
|
|
| [26] |
Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. Science, 2010, 327(5971): 1345-1350.
doi: 10.1126/science.1177319
pmid: 20223979
|
|
|
| [27] |
Chanan-Khan A A, Swaika A, Paulus A, et al. Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer Journal, 2013, 3(9): e143.
doi: 10.1038/bcj.2013.38
|
|
|
| [28] |
Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia, 2012, 26(11): 2326-2335.
doi: 10.1038/leu.2012.119
pmid: 22552008
|
|
|
| [29] |
Fischer E S, Böhm K, Lydeard J R, et al. Structure of the DDB1-CRBN E 3 ubiquitin ligase in complex with thalidomide. Nature, 2014, 512(7512): 49-53.
doi: 10.1038/nature13527
|
|
|
| [30] |
Ozawa Y, Sugi N H, Nagasu T, et al. E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo. European Journal of Cancer, 2001, 37(17): 2275-2282.
pmid: 11677118
|
|
|
| [31] |
Funahashi Y, Sugi N H, Semba T, et al. Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. Cancer Research, 2002, 62(21): 6116-6123.
pmid: 12414636
|
|
|
| [32] |
Abbate F, Casini A, Owa T, et al. Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorganic & Medicinal Chemistry Letters, 2004, 14(1): 217-223.
doi: 10.1016/j.bmcl.2003.09.062
|
|
|
| [33] |
Mayor-Ruiz C, Bauer S, Brand M, et al. Rational discovery of molecular glue degraders via scalable chemical profiling. Nature Chemical Biology, 2020, 16(11): 1199-1207.
doi: 10.1038/s41589-020-0594-x
|
|
|
| [34] |
Słabicki M, Kozicka Z, Petzold G, et al. The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K. Nature, 2020, 585(7824): 293-297.
doi: 10.1038/s41586-020-2374-x
|
|
|
| [35] |
Winter G E, Buckley D L, Paulk J, et al. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science, 2015, 348(6241): 1376-1381.
doi: 10.1126/science.aab1433
pmid: 25999370
|
|
|
| [36] |
Békés M, Langley D R, Crews C M. PROTAC targeted protein degraders: the past is prologue. Nature Reviews Drug Discovery, 2022, 21(3): 181-200.
doi: 10.1038/s41573-021-00371-6
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
